PER® Tumor Board: Charting a New Course in the Treatment of Newly Diagnosed Multiple Myeloma

Release Date: January 7, 2026

Expiration Date: January 7, 2027

Activity Overview

Advances in therapy for newly diagnosed multiple myeloma (NDMM) have improved survival, but relapse remains common, and treatment decisions are increasingly complex. Quadruplet regimens that include anti‑CD38 antibodies and next-generation proteasome inhibitors are transforming care for both patients who are eligible for transplant and those who are not, offering new opportunities along with important practical challenges.

In this CME‑certified hybrid symposium, internationally recognized experts present the latest evidence from landmark clinical trials and translate these findings into real‑world practice. Participants will receive practical guidance on assessing transplant eligibility, optimizing induction and maintenance therapy, and personalizing treatment while balancing efficacy, toxicity, and patient preferences. They will also learn strategies to manage adverse events and gain insight into emerging approaches, including cellular therapies, bispecific antibodies, and antibody drug conjugates.

This educational activity is an archive of the live presentation held on December 5, 2025.

For more information about this educational activity, the faculty, and disclosures, please click here.

Target Audience

This educational activity is directed toward physicians, nurses, nurse practitioners, physician assistants, pharmacists, and other health care providers involved in the diagnosis and treatment of multiple myeloma.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

• Evaluate disease- and patient-specific characteristics that contribute to assessment of transplant eligibility in patients with newly diagnosed multiple myeloma (NDMM)
• Incorporate efficacy and safety data from landmark clinical trials of novel therapeutic approaches into individualized treatment plans for patients with NDMM
• Tailor maintenance therapy strategies based on prior treatments, disease risk, and treatment response
• Provide evidence-based supportive care measures to prevent and manage treatment-related adverse events in patients with NDMM